Novartis (NVS) Stock Forecast & Price Target

$115.64

+1.87 (+1.64%)

(As of 10/9/2024 ET)

Novartis - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 8 Analyst Ratings

Sell
1

Hold
7

Buy
0

Based on 8 Wall Street analysts who have issued ratings for Novartis in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 8 analysts, 1 has given a sell rating, and 7 have given a hold rating for NVS.

Consensus Price Target

$120.70
4.38% Upside

According to the 8 analysts' twelve-month price targets for Novartis, the average price target is $120.70. The highest price target for NVS is $130.00, while the lowest price target for NVS is $114.00. The average price target represents a forecasted upside of 4.38% from the current price of $115.64.

Get the Latest News and Ratings for NVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novartis and its competitors.

NVS Analyst Ratings Over Time

Type	Current Forecast 10/10/23 to 10/9/24	1 Month Ago 9/10/23 to 9/9/24	3 Months Ago 7/12/23 to 7/11/24	1 Year Ago 10/10/22 to 10/10/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)
Hold	7 Hold rating(s)	6 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$120.70	$118.38	$118.13	$85.00
Forecasted Upside	4.38% Upside	1.04% Upside	6.89% Upside	-13.68% Downside
Consensus Rating	Reduce	Reduce	Hold	Hold

Bigger Than Nvidia? (Ad)

Bigger Than Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that's all they'll talk about.

Go here now for this breaking story.

NVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novartis Stock vs. The Competition

Type	Novartis	Medical Companies	S&P 500
Consensus Rating Score	1.88	2.79	2.50
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	4.47% Upside	11,088.45% Upside	7.37% Upside
News Sentiment Rating	Positive News See Recent NVS News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/11/2024	Bank of America 4 of 5 stars		Downgrade	Buy ➝ Neutral	$135.00 ➝ $130.00	+11.08%
9/5/2024	The Goldman Sachs Group 2 of 5 stars	J. Quigley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$119.00 ➝ $121.00	+1.37%
9/3/2024	Jefferies Financial Group 2 of 5 stars		Downgrade	Buy ➝ Hold
7/19/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
6/24/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Field Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
4/24/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$114.00 ➝ $116.00	+18.89%
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight	$114.00	+5.09%
12/18/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
4/19/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$75.00 ➝ $85.00	-13.28%
1/26/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
1/3/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Neutral
12/14/2022	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	CHF 82 ➝ CHF 84
12/5/2022	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 11:26 PM ET.

Should I Buy Novartis Stock? NVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 6, 2024. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

Novartis
Bull Case

Here are some ways that investors could benefit from investing in Novartis AG:

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally, focusing on therapeutic areas such as cardiovascular, renal, metabolic, and immunology.
Novartis AG offers prescription medicines for patients and physicians, providing a wide range of healthcare solutions.
Recent developments in Novartis AG's product pipeline show promising advancements in the healthcare industry.
Novartis AG's current stock price is favorable for potential investors, offering a good entry point for investment.
The company's global presence and diversified portfolio provide stability and growth opportunities for investors.

Novartis
Bear Case

Investors should be bearish about investing in Novartis AG for these reasons:

Novus Energy, Inc. (Novus) is a junior oil and gas company, not related to Novartis AG, which may cause confusion for investors looking for information on the healthcare company.
Novus Energy, Inc. focuses on resource plays in Western Canada, which is unrelated to Novartis AG's healthcare products and services.

NVS Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Novartis is $120.70, with a high forecast of $130.00 and a low forecast of $114.00.
: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There is currently 1 sell rating and 7 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" NVS shares.
: According to analysts, Novartis's stock has a predicted upside of 4.38% based on their 12-month stock forecasts.
: Over the previous 90 days, Novartis's stock had 2 downgrades by analysts.
: Novartis has been rated by research analysts at Bank of America, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, and The Goldman Sachs Group in the past 90 days.
: Analysts like Novartis less than other "medical" companies. The consensus rating for Novartis is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVS compares to other companies.